115 results on '"Bursi, S."'
Search Results
2. NUTRITIONAL STATUS AND BODY COMPOSITION EVALUATION IN A COHORT OF AMYOTROPHIC LATERAL SCLEROSIS PATIENTS IN BOLOGNA
3. EARLY NUTRITION PROTOCOL FOR IN- AND OUT-PATIENTS DURING COVID-19 PANDEMIC
4. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
5. Genome-wide association study identifies an early onset pancreatic cancer risk locus
6. Body composition assessment in patients undergoing radiotherapy for head and neck cancer
7. Early nutrition protocol during Covid-19 pandemic
8. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
9. A multifactorial score for pancreatic ductal adenocarcinoma risk prediction
10. Genome-wide association study identifies an early onset pancreatic cancer risk locus
11. SLC22A3 polymorphisms may influence overall patient survival-PANDORA study
12. Prevalence Of Fatty Liver And Its Association With Cardiovascular Disease In Patients With Familial Hypercholesterolemia
13. Efficacy And Safety Of Pcsk9 Inhibitors: The Real-Life Experience Of The Lipid Clinic In Modena, Italy
14. Occhio al Drusen
15. Bridging the gap between clinical practice and research: The association for research in psychiatry
16. Association of blood pressure with anxiety and depression in a sample of primary care patients
17. 'Quando scendono le ovaie...'
18. Is low blood pressure always healthy? Evidence of an inverse association between depressive symptoms and arterial blood pressure in a primary care sample
19. Is hyperglycemia associated with anxious-depressive symptoms? An Italian study in primary care setting
20. Association between anxiety and depressive symptoms with metabolic syndrome in primary care: Results of an Italian cross-sectional study involving outpatients
21. Apple or Pear? a Cross-sectional Study On the Association Between Body Shape and Symptoms of Anxiety and Depression in Primary Care Female Patients
22. Association Between Symptoms of Anxiety and Depression and BMI in Primary Care Patients: a Cross Sectional Study.
23. Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)
24. Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
25. Retrospective analysis of concomitant treatment with 3-dimensional conformal radiotherapy and temozolomide in high-grade glioma patients
26. Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with aggressive B-cell non-Hodgkin’s lymphoma (NHL)
27. Docetaxel (D) Plus Prednisone (P) in Combination with Metronomic Cyclophosphamide (CTX) and Celecoxib (C) as First Line Treatment in Metastatic Hormone Refractory Prostate Cancer (MHRPC): a Phase II Clinical Trial with Pharmacodynamic Evaluation
28. Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report
29. Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
30. Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases
31. First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts)
32. Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
33. Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
34. Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL)
35. First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
36. First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group
37. Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.)
38. EPA-1226 – Consultation-liaison psychiatry and the “women wellness project”: analysis of the association between cardiovascular risk factors and psychiatric symptoms in postmenopausal women.
39. 598 – The sixth criterion of the metabolic syndrome
40. 7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)
41. Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)
42. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
43. A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
44. Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
45. 3022 POSTER Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases
46. 3051 POSTER Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
47. 3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
48. The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
49. Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)
50. Docetaxel-prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.